

RELISH PHARMACEUTICALS LTD

PART I

Statement of Standalone Unaudited Results for the Quarter Ended 31/12/2015

(In lacs)

Particulars	3 Months Ended	3 Months Ended	3 Months Ended	9 Months Ended	9 months ended	Year to date
	(31-12-2015)	(30-09-2015)	31-12-2014	(31-12-2015)	(31-12-2014)	figures for current period ended (31/03/2015)
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Income from operations						
(a) Net sales/income from operations (Net of excise duty)	36.58	92.24	38.41	158.62	224.36	263.78
(b) Other operating income	0.00	50.00	0.00	100.00	0.00	0.00
Total income from operations (net)	36.58	142.24	38.41	258.62	224.36	263.78
2 Expenses						
(a) Cost of materials consumed	20.71	20.46	16.31	65.63	124.92	139.86
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00	0.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-31.53	66.05	-8.83	1.58	-10.77	(18.37)
(d) Employee benefits expense	27.29	27.35	26.02	88.99	84.84	108.08
(e) Depreciation and amortisation expense	15.00	15.00	16.00	45.00	48.00	60.00
(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	11.88	4.67	8.61	45.49	33.66	43.65
Total expenses	43.35	133.53	58.11	246.69	280.65	333.22
3 Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	(6.77)	8.71	(19.70)	11.93	(56.29)	(69.44)
4 Other income	0.63	0.38	10.39	1.94	53.90	64.58
5 Profit / (Loss) from ordinary activities before finance costs and exceptional items (3 + 4)	(6.14)	9.09	(9.31)	13.87	(2.39)	(4.86)
6 Finance costs	0.00			0.00	0.00	0.13
7 Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5 + 6)	(6.14)	9.09	(9.31)	13.87	(2.39)	(4.99)
8 Exceptional items	0.00			0.00	0.00	30.85
9 Profit / (Loss) from ordinary activities before tax (7 + 8)	(6.14)	9.09	(9.31)	13.87	(2.39)	25.86
10 Tax expense - Provision for taxation	0.00			0.00	0.00	13.62
11 Net Profit / (Loss) from ordinary activities after tax (9 + 10)	(6.14)	9.09	(9.31)	13.87	(2.39)	12.24
12 Extraordinary items	0.00	0.00	0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11 + 12)	(6.14)	9.09	(9.31)	13.87	(2.39)	12.24
14 Share of profit / (loss) of associates*	0.00	0.00	0.00	0.00	0.00	0.00
15 Minority interest *	0.00	0.00	0.00	0.00	0.00	0.00
16 Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15) *	(6.14)	9.09	(9.31)	13.87	(2.39)	12.24
17 Paid-up equity share capital (Face Value of the Share shall be indicated)	156.57	156.57	156.57	156.57	156.57	156.57
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00	0.00
19.i Earnings per share (before extraordinary items) (of Rs.10/- each) (not annualised):						
(a) Basic	(0.04)	0.06	(0.06)	0.09	(0.02)	0.08
(b) Diluted	(0.04)	0.06	(0.06)	0.09	(0.02)	0.08
19.ii Earnings per share (after extraordinary items) (of Rs. 10/- each) (not annualised):						
(a) Basic	-0.04	0.06	-0.06	0.09	-0.02	0.08
(b) Diluted	-0.04	0.06	-0.06	0.09	-0.02	0.08

- Notes: 1. The above results were reviewed by Audit Committee and taken on record by the Board of Directors at its meeting held on 12th February 2016
2. The Company has only single Reportable Business Segment in terms of requirements of Accounting Standard 17.
3. Previous quarter's figures have been re-grouped / re-arranged wherever necessary.

Place : Ahmedabad

Date : 12/02/2016



For Relish Pharmaceuticals Limited

PART II

Quarter Ended 31/12/2015						
Particulars	3 months Ended (31/12/2015)	3 months Ended (30/09/2015)	3 months Ended (31/12/2014)	9 Months Ended (31-12-2015)	9 months ended (31-12-2014)	Year to date figures for current period ended (31/03/2015)
A PARTICULARS OF SHAREHOLDING						
1 Public shareholding						
- Number of shares	769770	769770	769770	769770	769770	769770
- Percentage of shareholding	49.17%	49.17%	49.17%	49.17%	49.17%	49.17%
2 Promoters and Promoter Group Shareholding **						
a) Pledged/Encumbered						
- Number of shares	0.00	0.00	0.00	0.00	0.00	0.00
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
- Percentage of shares (as a % of the total share capital of the company)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
b) Non-encumbered						
- Number of shares	795905	795905	795905	795905	795905	795905
- Percentage of shares (as a % of the total shareholding of the Promoter and Promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	50.83%	50.83%	50.83%	50.83%	50.83%	50.83%

Particulars	3 months ended 31/12/2015
B INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	
Received during the quarter	
Disposed of during the quarter	
Remaining unresolved at the end of the quarter	



RELISH PHARMACEUTICALS LTD

(In Lacs)

STATEMENT OF ASSETS AND LIABILITIES		STANDALONE	
		As at 31.12.2015	As at Previous year end 31.3.2015
		(Unaudited)	(Audited)
A	EQUITY AND LIABILITIES		
	1 SHAREHOLDERS FUNDS		
	(a) Share Capital	157.00	157
	(b) Reserves and surplus	1232.74	1238
	(c) Money received against share warrant		
	SHAREHOLDERS FUNDS	1389.74	1395
	2 SHARE APPLICATION MONEY PENDING ALLOTMENT		
	3 NON - CURRENT LIABILITIES		
	(a) Long-term borrowing	3.60	116
	(b) Deferred tax liabilities (net)	228.65	229
	(c) Other long-term liabilities	0.00	0
	(d) long-term provisions	0.00	0
	NON - CURRENT LIABILITIES	232.25	345
	4 CURRENT LIABILITIES		
	(a) Short-term borrowing		38
	(b) Trade payables	31.00	42
	(c) Other current liabilities	0	0
	(d) Short-term provision	1.82	7
	CURRENT LIABILITIES	32.82	88
	TOTAL EQUITY AND LIABILITIES	1654.81	1828
B	ASSETS		
	1 NON - CURRENT ASSETS		
	(a) Fixed assets	1132.00	1140
	(b) Non-current investments	4	3
	(c) Deferred tax assets (net)	0	0
	(d) long-term loans and advances	0	0
	(e) Other non-current assets	0	7
	NON - CURRENT ASSETS	1136	1150
	2 CURRENT ASSETS		
	(a) Current investments	0	0
	(b) Inventories	113.29	132
	(c) Trade receivables	45.04	48
	(d) Cash and cash equivalents	52.44	49
	(e) Short-term loans and advances	252.45	385
	(f) Other current assets	55.94	63
	CURRENT ASSETS	519.16	677
	TOTAL ASSETS	1654.81	1828

